“Advancements in Genetic Testing and Early Diagnosis”
- A significant and accelerating trend in the Middle East and Africa multiple hereditary exostosis (MHE) market is the growing adoption of advanced genetic testing and imaging technologies, which are enhancing early diagnosis and personalized care strategies for affected individuals across the region
- For instance, leading healthcare institutions in countries such as the UAE and South Africa are increasingly incorporating next-generation sequencing (NGS) and MRI-based monitoring into standard care practices for rare skeletal disorders such as MHE
- Genetic testing enables early identification of the EXT1 and EXT2 gene mutations responsible for MHE, facilitating timely interventions and improved clinical outcomes. Institutions in Saudi Arabia and Egypt have begun partnering with international genetic laboratories to expand accessibility to these diagnostic tools
- The availability of MRI and CT scans in tertiary care centers allows for accurate mapping of tumor growth and skeletal deformities, supporting better surgical planning and long-term monitoring
- These diagnostic advancements are contributing to a shift toward more proactive disease management, empowering healthcare providers to design individualized treatment pathways and delay or prevent functional impairments
- As awareness of MHE grows among medical professionals and patients, the demand for comprehensive diagnostic evaluations is expected to rise, further strengthening the role of precision medicine in the rare disease landscape of the MEA region
